Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry — REMODALLO  

Myeloid Leukemia, Acute Clinical Trial

Official title: Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry Coupled With FRAX / TBS in Allo-HSCT

Status Not yet recruiting

Clinical Trial Summary

Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.

Clinical Trial Description

Allo-HSCTs performed for the treatment of hematologic malignancies has been increasing in recent years. There is therefore a growing interest in the quality of life of these patients and in particular for the bone complications of the transplant. Indeed, it was found a high incidence of osteoporosis / osteopenia in this population associated with an increased risk of osteoporotic fracture from 6 to 9 times compared to the general population.

This study will evaluate the variation of mineral density and bone microarchitecture parameters by bone densitometry with measurement of trabecular bone score and fracturing risk before and after allogeneic HSCTs transplant, at predefined times. It's also evaluating pain scale, fracture incidence and bone remodeling markers. ;

Related Conditions & MeSH terms

• Leukemia, Myeloid, Acute
• Myeloid Leukemia, Acute

• NCT number: NCT05161026
• Study type: Interventional
• Source: University Hospital, Caen
• Contact: Agathe FARGE, PhD
• Phone: +33 2.31.27.21.40
• Email: farge-a@chu-caen.fr
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 10, 2021
• Completion date: December 1, 2027